Keratitis Market

Market Overview:

The 7 major keratitis markets are expected to exhibit a CAGR of 5.04% during 2024-2034.

The keratitis market has been comprehensively analyzed in IMARC's new report titled "Keratitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Keratitis refers to an inflammation or infection of the cornea, the transparent, dome-shaped surface that covers the front of the eye. This condition mainly damages the external structures of the eye, such as the cornea and the surrounding tissues. The symptoms of the disease include eye pain and discomfort, redness, blurred vision, sensitivity to light (photophobia), excessive tearing or discharge, the feeling of a foreign body in the eye, etc. In severe cases, individuals suffering from the ailment may also experience corneal ulcers or perforations, leading to vision loss or even blindness. The diagnosis of keratitis typically involves a comprehensive eye examination, including a detailed medical history and evaluation of symptoms. A healthcare provider will also perform a slit-lamp examination that helps to identify the presence of infiltrates, such as inflammatory cells or infectious agents, in patients. If an infection is suspected as the cause of keratitis, a corneal culture is further recommended to determine the specific microorganism triggering the illness. Additionally, anterior segment photography is utilized to detect the extent and progression of the disease.

The rising incidences of bacterial, viral, fungal, or parasitic infections, in which the microorganisms directly invade the cornea, leading to damage and inflammation, are primarily driving the keratitis market. In addition to this, the increasing prevalence of various associated risk factors, like dry eyes, exposure to irritants, autoimmune disorders, eye injury or trauma, allergic reactions, etc., is further acting as a significant growth-inducing factor. Moreover, the inflating utilization of effective drugs, such as antibiotics, antifungals, antivirals, etc., to treat the infection and inhibit disease progression in patients is also creating a positive outlook for the market. Additionally, the widespread application of artificial tears or lubricating eye drops, since they help to maintain a stable and healthy tear film by moisturizing the ocular surface and reducing discomfort, is further propelling the market growth. Besides this, the emerging popularity of phototherapeutic keratectomy, which involves using an excimer laser to precisely remove the superficial layers of the cornea, thereby eliminating the infected or scarred tissue and promoting the regeneration of robust cells, is expected to drive the keratitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the keratitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for keratitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the keratitis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the keratitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the keratitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current keratitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the keratitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the keratitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the keratitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of keratitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of keratitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of keratitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with keratitis across the seven major markets?
• What is the size of the keratitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of keratitis?
• What will be the growth rate of patients across the seven major markets?
   

Keratitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for keratitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the keratitis market?
• What are the key regulatory events related to the keratitis market?
• What is the structure of clinical trial landscape by status related to the keratitis market?
• What is the structure of clinical trial landscape by phase related to the keratitis market?
• What is the structure of clinical trial landscape by route of administration related to the keratitis market?